About

Angela Belcher is a James Mason Crafts Professor and a Professor of Materials Science and Engineering and Biological Engineering at MIT. She is a materials chemist with expertise in biomaterials, biomolecular materials, organic-inorganic interfaces, and solid-state chemistry. Her work focuses on evolving organisms to build new materials and devices for applications in clean energy, electronics, the environment, and medicine. Professor Belcher received a BS in creative studies in 1991 and a PhD in inorganic chemistry from the University of California, Santa Barbara in 1997. She has been recognized with numerous awards, including the 24th annual MacArthur Foundation Fellowship, the 2004 Four Star General Recognition Award, and was named Scientific American’s Research Leader of the Year in 2006. Her research has been published in prestigious journals such as Science and Nature, and her work has been reported in various publications including Fortune, Forbes, Discover, The New York Times, and The Wall Street Journal. In 2022, she was elected as a member of the National Academy of Sciences, and she has also been honored as a Fellow of the National Academy of Engineers and the National Academy of Inventors, as well as receiving the Lemelson-MIT Prize.

Research topics

• Chemistry
• Biochemistry
• Nanotechnology
• Environmental chemistry
• Immunology
• Biology
• Medicine
• Environmental engineering
• Ecology
• Optics
• Biophysics
• Materials science
• Waste management
• Environmental science

Selected publications

• Abstract A049: CD8+ T cell decline from regression to recurrence in ovarian cancer is linked to expansion of suppressive macrophages

  Cancer Immunology Research · 2026-02-18

  article

  Abstract High grade serous ovarian cancer (HGSOC) is the most common and deadliest form of ovarian cancer. Recurrence after chemotherapy remains a major challenge, particularly in homologous recombination proficient (HRP) patients. However, the interval of low tumor burden between therapy-induced remission and recurrence presents an ideal window to engage the immune system. Our work aims to characterize the immune microenvironment of HRP HGSOC throughout post-chemotherapy recurrence to understand mechanisms of suppression and identify potential targets for immunotherapy. To study immune responses in pre- and post-treatment HRP HGSOC, we utilized syngeneic murine models. These models were derived from the CPAK.SIY cell line, driven by Ccne1 OE , p53 R172H , Akt2 OE , and Kras G12V and engineered to express the model antigen SIY. To model pre- and post-chemotherapy states, we in vivo passaged CPAK.SIY in the presence of carboplatin/paclitaxel chemotherapy or vehicle. The resulting derivatives are termed CPAK.SIYP1 (chemotherapy-sensitive) and CPAK.SIYCHEM (chemotherapy-resistant). Upon chemotherapy treatment, CPAK.SIYP1 recapitulates the initial regression observed following frontline therapy, while CPAK.SIYCHEM models resistance. We utilized OVASEEK, a whole-organ ex vivo imaging platform, to detect and isolate early tumor lesions followed by immunofluorescence to profile post-treatment spatial dynamics. We observed CD8+ T cell infiltration in CPAK.SIYP1 tumors decreased upon chemotherapy treatment. CD8+ T cells that remained in the tumor after chemotherapy expressed higher levels of CD25 and Granzyme B, as measured by flow cytometry, displaying a potential for increased effector function. Interestingly, CPAK.SIYCHEM tumors, modeling a resistant state, did not show increased immunity. In fact, CD8+ T cells in CPAK.SIYCHEM tumors expressed strikingly low levels of Granzyme B. This indicates that CD8+ T cell responses mounted during initial chemotherapy may not persist as recurrent disease progresses. To mechanistically understand how initial chemotherapy mediates an immune evasive state, we performed single-cell RNA sequencing (scRNAseq) on CPAK.SIYP1 and CPAK.SIYCHEM tumors with and without chemotherapy treatment. Analysis of scRNAseq data indicated that in all tumors, the immune compartment was dominated by macrophages. Most macrophages scored highly for suppressive tumor-associated macrophage (TAM) signatures. Notably, the two macrophage populations that appeared most suppressive were enriched in chemotherapy-treated tumors, implicating a role for these TAMs in shaping the tumor microenvironment and inhibiting CD8+ T cell activation during disease recurrence. Together, these findings suggest that while chemotherapy initially enhances CD8+ effector T cells, the resulting tumor microenvironment evolves to become highly suppressive, contributing to immune evasion. Specifically, the enrichment of highly suppressive TAM populations during this transition highlights them as key drivers of post-treatment immune dysfunction and promising targets for immunotherapy. Citation Format: Grace Wolczanski, Emma Schuler, Margaret Billingsley, Mae Pryor, Samuel Freeman, Neelkanth Bardhan, Vivek Rastogi, Fiona Chatterjee, Richard Van, Angela Belcher, Sohrab Shah, Paula Hammond, Stefani Spranger. CD8+ T cell decline from regression to recurrence in ovarian cancer is linked to expansion of suppressive macrophages [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr A049.

  PublisherDOI

• A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy

  Advanced Materials · 2025-08-27 · 1 citations

  articleOpen accessSenior authorCorresponding

  Abstract Nanovaccines co‐assemble antigens and adjuvants to elicit robust immune responses but often require complex synthesis and post‐modification procedures. Here, a programmable nanovaccine platform based on the M13 bacteriophage is developed for the scalable production of vaccines and single‐step modular engineering of adjuvanticity, length, and antigen density. By reprogramming the sequence and size of the noncoding phage genome, the Toll‐like receptor 9 activation and the length of the phage are precisely controlled. With a novel molecular engineering approach, the antigen density is tuned from 13.6% to 70.3%. A systematic modulation reveals an optimal adjuvanticity at a constant antigen density for maximum anti‐tumor CD8 + T cell response, and vice versa, using the model antigen SIINFEKL. The M13 phage‐based nanovaccine induces durable memory immunity lasting over a year. In addition, a 24‐fold increase in neoantigen‐specific CD8 + T cell frequency is achieved when increasing both the adjuvanticity and antigen density. Furthermore, when combined with anti‐PD‐1 therapy, the M13 phage‐based personalized vaccine eradicates established MC‐38 tumors in 75% of treated animals and they develop 100% resistance against tumor invasion when challenged 5 months after treatment. These findings establish M13 phage as a powerful and versatile nanovaccine platform with transformative potential for personalized cancer immunotherapy.

  PublisherOA PDFDOI

• In Situ Crosslinking of Bioorthogonal Nanoparticles to Restore Clot Stability in Coagulopathic Blood

  BIO-PROTOCOL · 2025-01-01

  articleOpen access

  Intravenous hemostats have shown significant promise in prolonging survival for severe noncompressible and internal injuries in preclinical animal models. Existing approaches include the use of liposomes with or without procoagulant enzymes, as well as polymer nanoparticles or soluble biopolymers. While these methods predominantly target or mimic tissue components that are present during coagulation, such as activated platelets and collagen, they may not account for the loss of fibrinogen, which is not only key to clot formation but also the first protein to fall below critical levels in dilutional coagulopathy. This protocol describes the synthesis and in vitro or ex vivo characterization of a crosslinkable nanoparticle system that seeks to address dilutional coagulopathy by leveraging the critical gelation concentration and bioorthogonal click chemistry. The system was shown to only gel at high nanoparticle and crosslinker concentrations, increase the rate of platelet recruitment, and decrease the rate of clot degradation in a low-fibrinogen environment, providing a platform for treating severe hemorrhage in a coagulopathic environment. Ultimately, the contents of this protocol may assist researchers in the in vitro characterization and screening of other crosslinkable nanoparticle systems or hemostats, with potential expansions to other categories of coagulation dysfunction, such as embolism treatment. Key features • A protocol for the synthesis of nanoparticles with activated-platelet-binding moieties to mimic fibrin. • In vitro and ex vivo assays assessing complement activation, accumulated platelet recruitment, platelet recruitment under hemodilution, coagulation potential, and clot lysis. • The inclusion of hemodiluted and plasminolytic conditions creates a more physiologically relevant environment for screening of hemostatic agents. • The use of a two-component system helps reduce complement activation in intravenous therapies.

  PublisherDOI

• Visualization and cellular uptake of carbon dots in ovarian cancer cells using label-free optical microscopy

  2025-12-16

  articleSenior author

  Carbon dots (CDs) have emerged as a cutting-edge nanomaterial for bioimaging, offering exceptional photostability, tunable fluorescence, biocompatibility, and low toxicity. This study presents a label-free microscopy approach to analyze CDs interactions with ovarian cancer cells and their cellular dynamics.

  PublisherDOI

• Abstract 3657: Optimal prescriptive treatments for ovarian cancer with genetic data

  Cancer Research · 2025-04-21

  article

  Abstract Among the cancers affecting the female population, Ovarian Cancer (OC), while being relatively rare, is the leading cause of gynecological cancer-related deaths, with overall 5-year survival rates of approximately 50% for all stages combined. This is because of the challenges associated with the diagnosis, resulting in detection at advanced stages of OC, coupled with the slow progress in effective treatment options since the approval of platinum-based chemotherapy in the late 1970s. There has been a relative lack of sophisticated methods based on Machine Learning (ML) models that use genetic data for better prediction of Ovarian Cancer outcomes and result in more effective treatment recommendations. Therefore, there is an unmet clinical need to create models that allow physicians to make informed decisions based on all available data, including patient demographic, social, health, and genomic data. Hence, we develop new techniques for leveraging genetic information in prescribing optimal treatments for patients with OC, using a publicly available dataset from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) trial. Our approach is able to transform genotype sequencing information into a simple tabular form that can then be used as the input to any ML model. Coupled with the recorded treatment regimen and clinical parameters of matched patients from the genetic dataset, we estimate the treatment effect in terms of mortality prediction and use it to prescribe the optimal treatment for any given patient. By including the genetic features engineered through our proposed method, our models have a higher accuracy than the models without genetic information embedded. The increase in predictive accuracy demonstrates the improved efficacy of our method in the predictive setting. Furthermore, in the prescriptive setting, the models including genetic features output different treatment choices for patients, showing the impact of their inclusion. This is further highlighted by the feature importance of the genetic features such as mutations in the FAT3, BRCA1, BRCA2, and NF1 genes, where they rank highly with a tighter aggregation of the top features, relative to the sharp drop-off in feature importance after the top feature in the models without genetic data. Taken together, in summary, our models will allow oncologists to make more informed and accurate decisions, incorporating a patient's genetic data with all other available clinical information, which has the potential for improved prognosis and better long-term survival outcomes for Ovarian Cancer patients. Citation Format: Alkiviadis Mertzios, Matea Gjika, Xidan Xu, Samayita Guha, Neelkanth M. Bardhan, Subodha Kumar, Angela Belcher, Georgia Perakis. Optimal prescriptive treatments for ovarian cancer with genetic data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3657.

  PublisherDOI

• Functionalization of rare-earth nanoparticles with hybrid silica-lipid shells for T-cell labeling

  Biomaterials Science · 2025-01-01

  articleOpen accessSenior author

  (Yb, Er) nanoparticles with hybrid silica-lipid shells and demonstrate successful and stable labelling of immune cells (T-lymphocytes) for the formation of near-infrared fluorescent immune cells. We use super-resolution microscopy to characterize cell labeling at nanoscale resolution and show individual nanoparticles bound or internalized to T-cells. These surface medication methods are modular and customizable to enable targeting to a variety of cell types, with the potential for broad applications in a variety of disease phenomena such as non-invasive visualization of cell-based therapies.

  PublisherOA PDFDOI

• Abstract 2810: Intracellular tumor microbiota promotes metastasis and drives an immunosuppressive phenotype in ovarian cancer

  Cancer Research · 2024-03-22

  articleSenior author

  Abstract Background: The tumor microenvironment has immense potential to change a patient’s prognosis and therapeutic response. One of the emerging components of interest in the tumor microenvironment is the presence of intracellular microbes. Numerous studies have focused on colon and pancreatic cancer because of their proximity to the commensals in the gut. The female reproductive system is another site in our body where the rich vaginal microbiome has the potential to affect nearby organs and impact diseases. However, there is still little investigation done to understand the impact of microbes on Ovarian Cancer (OC). Objective: To understand the role of the microbiome in OC metastasis, to develop new therapies to target the tumor microbiome Methods: We used a co-culture study, the parameters of which were optimized to study the infection of microbes in different cell lines. Using a wide array proteome profiler, we looked for cytokines and chemokines to understand changes in signaling post-infection. Protein levels in the conditioned media using ELISA. Changes in actin, paxillin, and LC3B (autophagy marker) were monitored using immunofluorescence microscopy and western blots. Migration was studied by using transwell assay and spheroid cultures. Results: We have identified two species of bacteria preferentially enriched in human ovarian tumors based on recent findings in the literature. We have demonstrated that these microbes are better at infecting OC cells in vitro over non-specific bacteria, can reside intracellularly, and are metabolically active. Upon infection, this intracellular uptake drives the release of pro-inflammatory cytokines and chemokine signaling by cancer and normal ovarian surface cells. We have also observed increased autophagy, changes in the actin cytoskeleton and reduced Paxillin foci on cancer cells infected with OC-associated microbes. This has led to increased migration in them; however, inactivated microbes did not change their migratory behavior. The infection also caused individual tumor cells to form more numerous and larger colonies when seeded into soft agar, suggesting an effect on cancer cell migration. Furthermore, we have shown that these microbes also elicit a more robust reaction in immune cells like Dendritic cells and macrophages, causing them to secrete chemokines like CCL 2,3,4,5, which also cause the cancer cells to migrate and have the potential to recruit neutrophils to drive the tumor microenvironment towards an immunosuppressive phenotype. Conclusion: Most ovarian cancer patients are diagnosed at Stage III/IV, where cancer has metastasized, and is unresponsive to immunotherapy as the cancer is considered “cold”. Through functional studies, we were able to gain insights into the role of the microbiome, which is associated with the clinical outcomes of OC, hoping to potentiate the existing therapies by probing the tumor microbiome. Citation Format: Ashutosh Kumar, Neelkanth Manoj Bardhan, Angela M. Belcher. Intracellular tumor microbiota promotes metastasis and drives an immunosuppressive phenotype in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2810.

  PublisherDOI

• Reprogramming the genome of M13 bacteriophage for all-in-one personalized cancer vaccine

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-11-23 · 1 citations

  preprintOpen accessSenior authorCorresponding

  Abstract Peptide-based vaccines face limitations in immunogenicity and stability, and challenges in co-delivering antigens and adjuvants effectively. Virus-based nanoparticles, particularly M13 bacteriophage, present a promising solution due to their genetic modifiability, intrinsic adjuvanticity, and efficient antigen presentation capabilities. Here we developed a programmable M13 phage-based personalized cancer vaccine enabling single-step antigen-adjuvant assembly. Specifically, we designed a reprogrammed (RP) phage platform that precisely regulates Toll-like receptor 9 activation by programming its genome sequence and modulates antigen density through genetic engineering. Vaccination studies with RP phages demonstrated that the immune response could be modulated by fine-tuning the adjuvanticity and antigen density, revealing an optimal antigen dose and adjuvanticity for maximum vaccine efficacy. The RP phage induced a remarkable 24-fold increase in neoantigen-specific CD8 + T cells and eradicated established MC-38 tumors when combined with anti-PD-1 therapy. These findings highlight the RP phage’s potential as a powerful nanovaccine platform for personalized cancer vaccines.

  PublisherOA PDFDOI

• A Machine Learning-Optimized System for Pulsatile, Photo- and Chemotherapeutic Treatment Using Near-Infrared Responsive MoS₂-Based Microparticles in a Breast Cancer Model

  ACS Nano · 2024-10-28 · 14 citations

  articleCorresponding

  Multimodal cancer therapies are often required for progressive cancers due to the high persistence and mortality of the disease and the negative systemic side effects of traditional therapeutic methods. Thus, the development of less invasive modalities for recurring treatment cycles is of clinical significance. Herein, a light-activatable microparticle system was developed for localized, pulsatile delivery of anticancer drugs with simultaneous thermal ablation by applying controlled ON–OFF thermal cycles using near-infrared laser irradiation. The system is composed of poly(caprolactone) microparticles of 200 μm size containing molybdenum disulfide (MoS2) nanosheets as the photothermal agent and hydrophilic doxorubicin or hydrophobic violacein, as model drugs. Upon irradiation, the nanosheets heat up to ≥50 °C leading to polymer softening and release of the drug. MoS2 nanosheets exhibit high photothermal conversion efficiency and require low-power laser irradiation. A machine learning algorithm was applied to acquire the optimal laser operation conditions. In a mouse subcutaneous model of 4T1 triple-negative breast cancer, 25 microparticles were intratumorally administered, and after 3-cycle laser treatment, the system conferred synergistic phototherapeutic and chemotherapeutic effects. Our on-demand, pulsatile synergistic treatment resulted in increased median survival up to 39 days post start of treatment compared to untreated mice, with complete eradication of the tumors at the primary site. Such a system is therapeutically relevant for patients in need of recurring cycles of treatment on small tumors, since it provides precise localization and low invasiveness and is not cross-resistant with other treatments.

  PublisherDOI

• Abstract 6166: A whole-organ <i>ex vivo</i> optical imaging technique for non-destructive, more precise identification of serous tubal intraepithelial carcinoma (STIC) in fallopian tubes

  Cancer Research · 2024-03-22

  articleSenior author

  Abstract Objective With the recent discovery of the fallopian tube (FT) origin of the most common and lethal type of ovarian cancer, high grade serous cancer (HGSC), engineering solutions to overcome the limitations of standard histopathology to more reliably identify incipient HGSCs and their serous tubal intraepithelial carcinoma (STIC) precursors are much needed. This investigation tests the potential of whole-organ ex vivo optical imaging of freshly excised FTs to label and sample abnormal tubal epithelium prior to formalin fixation and paraffin embedding for standard histopathology. Methods This investigation prototyped “OVASEEK”, a whole-organ, near-infrared optical imaging platform for identification of STICs. This prospective biospecimen protocol with annotated clinical data was approved by the IRB. Following salpingectomy at the time of hysterectomy for benign indications, FTs from study participants are longitudinally bivalved. Half of the FT is retained for routine evaluation using the Sectioning and Extensively Examining the Fimbriated end (SEE-FIM) protocol by Johns Hopkins gynecologic pathologists (Gyn Path), while the other half is sent overnight in organ transplant media to MIT for imaging on OVASEEK. Hyperspectral “label free” first pass imaging is performed using a series of band-pass filters. Second pass fluorescence imaging is then performed using nanoparticles tagged with anti-LAMC1 antibodies targeting laminin γ1, a known STIC surface marker. Abnormal signal(s) on OVASEEK imaging of the FT epithelium are tattooed with black ink, the tissue is formalin fixed and returned to Gyn Path for serial sectioning. Research findings are reported in an addendum to the formal pathology report in the electronic medical record and discussed with the patient by the gynecologic oncologist co-investigator. Results OVASEEK enabled non-destructive imaging over a wide field-of-view ~ 12×12 cm, with features of interest in the 1,050-1,550 nm range. In this pilot study, OVASEEK identified histopathologic abnormalities missed by standard SEE-FIM in 20% of FTs (n=2 out of 10). In each case, OVASEEK found microscopic (~200 µm) foci of salpingitis, a lymphoplasmacytic infiltrate consistent with inflammation. Performance of serial sectioning and histopathologic examination of the tattooed epithelium yielded this diagnosis. Conclusion Work is ongoing to improve the resolution, speed and sensitivity of OVASEEK for STIC detection. Identification of µm-sized foci of inflammation using OVASEEK is proof-of-principle that whole-organ ex vivo imaging of freshly excised FTs may be an innovation that improves the diagnostic performance of routine histopathology. Accurate and reproducible diagnosis of STIC and concurrent microscopic HGSC is imperative to the understanding of the early pathogenesis of HGSC in clinically actionable ways. Citation Format: Neelkanth M. Bardhan, Vivek Rastogi, Rebecca L. Stone, Angela M. Belcher. A whole-organ ex vivo optical imaging technique for non-destructive, more precise identification of serous tubal intraepithelial carcinoma (STIC) in fallopian tubes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6166.

  PublisherDOI

Recent grants

• NIH Grant U54CA151884

  NIH · $8.9M · 2016

Frequent coauthors

• Paula T. Hammond

  67 shared

• Jifa Qi

  Massachusetts Institute of Technology

  51 shared

• Ki Tae Nam

  Seoul National University

  28 shared

• Po‐Yen Chen

  26 shared

• Noémie‐Manuelle Dorval Courchesne

  McGill University

  26 shared

• Galen D. Stucky

  University of California, Santa Barbara

  24 shared

• Daniel E. Morse

  23 shared

• Xiangnan Dang

  Eli Lilly (United States)

  22 shared

Labs

• The Biomolecular Materials GroupPI

Education

• Ph.D., Materials Science and Engineering

  Massachusetts Institute of Technology

  1996

• B.S., Chemistry

  California Institute of Technology

  1991

Awards & honors

• 24th annual MacArthur Foundation Fellowship
• 2004 Four Star General Recognition Award
• Scientific American ’s Research Leader of the Year (2006)
• 2018 Xconomy Award, Innovation at the Intersection
• 2018 Fellow, National Academy of Engineers